VIRALEZE™ contains astodrimer sodium, which has been shown in clinical and laboratory studies to trap and block cold and respiratory viruses. 

Explore some of the scientific publications here.

Key Finding: Astodrimer Sodium demonstrated the ability to trap and block SARS-CoV-2 by over 99.9% within 1 minute of exposure, in laboratory studies.

Key finding: Astodrimer Sodium 1% Nasal Spray was found to be safe and well-tolerated, with no systemic absorption and only mild, self-limiting side effects. The findings support its potential as a safe and innovative topical barrier nasal spray for reducing a broad spectrum of respiratory virus infections.

Key Finding: Astodrimer Sodium significantly reduced the viral load in older patients, particularly those aged 45 and above, leading to faster viral clearance and a quicker recovery, including from symptoms like loss of smell.

Key Finding: When SARS-CoV-2 was pre-treated with Astodrimer sodium, there was a 99% reduction in infectious virus in the lung and trachea of mice, showing strong preventative effects when applied before infection.

Key Finding: These findings support VIRALEZE™ as a scientifically validated, nanotechnology-based solution for respiratory virus protection, leveraging a physical rather than immune-based antiviral approach.

Key Finding: Astodrimer sodium nasal spray effectively reduced infectious viruses while preserving mucociliary function, showing a benign cytotoxicity profile in human nasal epithelium models. Compared to other nasal sprays, astodrimer sodium nasal spray demonstrated a superior ability to block virus.